Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:activities |
inhibits angiogenesis
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2012
gptkb:FDA |
| gptkbp:category |
gptkb:unknown
Category C |
| gptkbp:class |
antineoplastic agent
VEGF inhibitor |
| gptkbp:clinical_trial |
cancer therapy
oncology NC T01113000 NC T01153025 NC T01321664 NC T01337324 NC T01337337 |
| gptkbp:contraindication |
uncontrolled hypertension
active bleeding history of thromboembolic events severe hepatic impairment hypersensitivity to ziv-aflibercept |
| gptkbp:dosage_form |
solution for infusion
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zaltrap
|
| gptkbp:indication |
metastatic colorectal cancer
second-line treatment combination with FOLFIRI |
| gptkbp:ingredients |
gptkb:ziv-aflibercept
C100 H145 N29 O33 S |
| gptkbp:interacts_with |
anticoagulants
other antineoplastic agents CY P450 inducers |
| gptkbp:invention |
2028
patented |
| gptkbp:is_used_for |
treatment of colorectal cancer
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:market |
gptkb:stock_market_index
|
| gptkbp:marketed_as |
gptkb:Zaltrap
|
| gptkbp:packaging |
vial
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
fatigue
nausea hypertension abdominal pain decreased appetite diarrhea thromboembolic events proteinuria stomatitis |
| gptkbp:storage |
store at 2° C to 8° C
|
| gptkbp:traded_on |
gptkb:Zaltrap
|